Prospective Studies on Radiation Therapy for Breast Cancer
A special issue of Current Oncology (ISSN 1718-7729). This special issue belongs to the section "Breast Cancer".
Deadline for manuscript submissions: 30 June 2027 | Viewed by 113
Special Issue Editors
Interests: breast cancer; prostate cancer; radiotherapy
Special Issue Information
Dear Colleagues,
Breast cancer remains the most commonly diagnosed malignancy worldwide, and radiotherapy continues to play a central role in its multidisciplinary management. While advances in treatment delivery—such as hypofractionation, intensity-modulated radiotherapy, image guidance, and proton therapy—have improved precision and reduced toxicity, the field is increasingly moving toward a more personalized and adaptive approach to care.
Key challenges remain in identifying which patients benefit most from radiotherapy, optimizing treatment sequencing with systemic therapies, and minimizing long-term toxicity while preserving excellent oncologic outcomes. At the same time, emerging tools such as artificial intelligence and biomarkers offer new opportunities to refine decision-making, streamline workflows, and individualize treatment.
This Special Issue will focus on prospective studies that advance innovation in breast radiotherapy, with an emphasis on personalization, integration, and equitable implementation. We particularly welcome research that informs how radiotherapy can be tailored, de-escalated, or intensified based on clinical, biological, and patient-centered factors, including early-phase and proof-of-concept prospective trials that explore novel strategies.
We aim to highlight prospective evidence that will shape the next generation of breast radiotherapy practice.
Topics of interest include, but are not limited to, the following:
- Prospective trials of hypofractionated and ultra-hypofractionated regimens, including de-escalation strategies;
- Treatment sequencing and integration, including preoperative radiotherapy and combination with systemic therapies (e.g., targeted agents, immunotherapy);
- Adaptive and personalized radiotherapy approaches, including response-guided treatment and risk stratification;
- Biomarkers of radiosensitivity, toxicity, and treatment response;
- Applications of artificial intelligence in treatment planning, target delineation, outcome prediction, and clinical decision support;
- Advances in treatment delivery (e.g., IMRT, image guidance, motion management, proton therapy), with a focus on clinical impact;
- Patient-reported outcomes, survivorship, and long-term toxicity;
- Equity, access to care, and implementation of evidence-based radiotherapy across diverse populations;
- Pragmatic trials, real-world prospective data, and proof-of-concept studies to inform and accelerate clinical innovation.
We look forward to hearing from you.
Dr. Michael Yassa
Dr. Tarek Hijal
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- breast cancer
- radiotherapy
- prospective clinical trials
- artificial intelligence
- preoperative radiotherapy
- adaptive radiotherapy
- biomarker-guided treatment
- treatment optimization
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
